Objective: To demonstrate that alvimopan (6 or 12 mg) accelerates recovery of gastrointestinal (GI) function in patients undergoing laparotomy for bowel resection or radical hysterectomy. Summary Background Data: Postoperative ileus (POI) following laparotomy may increase morbidity and extend hospitalization. Opioids can contribute to the duration of POI. Alvimopan is a novel opioid receptor antagonist in development for the management of POI. Methods: A total of 510 patients scheduled for bowel resection or radical hysterectomy were randomized (1:1:1) to receive alvimopan 6 mg, alvimopan 12 mg, or placebo orally Ն2 hours before surgery, then twice a day (b.i.d.) until hospital discharge or for up to 7 days. The primary efficacy end point was a composite of time to recovery of upper and lower GI function. An associated secondary end point was time to hospital discharge order written. Results: The modified intent-to-treat population included 469 patients (451 bowel resection and 18 radical hysterectomy patients). Time to recovery of GI function was accelerated for the alvimopan 6 mg (hazard ratio ͓HR͔ ϭ 1.28; P Ͻ 0.05) and 12 mg (HR ϭ 1.54; P Ͻ 0.001) groups with a mean difference of 15 and 22 hours, respectively, compared with placebo. The time to hospital discharge order written was also accelerated in the alvimopan 12 mg group (HR ϭ 1.42; P ϭ 0.003) with a mean difference of 20 hours compared with placebo. The incidence of adverse events was similar among treatment groups.
P atients undergoing major abdominal surgery are at a high risk of developing postoperative ileus (POI), which is characterized by a transient impairment of bowel function and reduced motility sufficient to prevent effective transit of intestinal contents. [1] [2] [3] Multiple factors are thought to contribute to the pathogenesis of POI, including physical manipulation of the bowel, surgical stress and inflammatory mediators (including endogenous opioids), changes in electrolyte and fluid balance, pharmacologic agents such as inhalation anesthetics, and use of opioids for postoperative analgesia. 4 Symptoms associated with POI include abdominal distension and bloating, nausea and/or vomiting, lack of bowel sounds, gas and fluid accumulation in the bowel, delayed passage of flatus or stool, and inability to tolerate a solid diet. [5] [6] [7] These symptoms can contribute to significant patient discomfort and related postoperative complications, making POI one of the most common causes of prolonged length of hospital stay following abdominal surgery. 5, 8 Furthermore, POI may be a significant contributing factor for hospital readmissions. 9, 10 Presently, there are no approved drug therapies for the management of POI. Current approaches, which are primarily directed at managing the symptoms of POI, yield inconsistent results and may actually contribute to increased morbidity. 4, 5, 11 Alvimopan is a novel, oral, peripherally acting antagonist of the opioid receptor that has limited ability to cross the blood-brain barrier and is currently being evaluated for the management of POI. [12] [13] [14] In an exploratory trial of 78 patients who underwent abdominal surgery, results showed that alvimopan accelerated the recovery of bowel function and shortened the duration of hospitalization without compromising patient-controlled analgesia. 15 The present study was performed to evaluate the efficacy and safety of alvimopan (6 or 12 mg) for the management of POI in patients undergoing partial bowel resection with primary anastomosis or radical hysterectomy.
MATERIALS AND METHODS
This was a randomized, double-blind, placebo-controlled, parallel-group study involving 34 centers in North America. The study protocol and informed consent form were approved by institutional review boards at each study site. Patients of both sexes were eligible for participation if they met the following criteria: at least 18 years of age, scheduled to undergo a partial small or large bowel resection with primary anastomosis or radical total abdominal hysterectomy (rTAH), scheduled to receive postoperative pain management with intravenous patient-controlled analgesia with opioids, and scheduled to have the nasogastric tube (NGT) removed at the end of surgery. Liquids were offered and ambulation encouraged on postoperative day (POD) 1 and solid food was offered on POD 2.
Patients were randomized to receive an oral dose of either alvimopan (6 mg or 12 mg) or identical placebo capsules at least 2 hours before surgery and then twice daily (b.i.d.) beginning on POD 1 until hospital discharge or for a maximum of 7 days of postoperative treatment.
The primary efficacy end point was the time to recovery of gastrointestinal (GI) function (GI-3) as defined by the later of the following 2 events: time that the patient first tolerates solid food and the time that the patient first passes either flatus or a bowel movement (BM). Because flatus can be subject to considerable variability, 16 a secondary end point (GI-2), also representing time to recovery of GI function, was defined by the later of the following 2 events: time that the patient first tolerates solid food and the time that the patient first passes a BM. Additional secondary efficacy endpoints included time (in hours) from the end of surgery to first flatus, first BM, tolerance of solid food, ready for hospital discharge (based solely on the recovery of GI function as defined by the surgeon), and time to discharge order written (DCO). Other postoperative variables that were monitored included pain (visual analog scale ͓VAS͔), the need for postoperative NGT insertion, opioid consumption, and severity of GI symptoms (eg, nausea, bloating). Adverse events (AEs) were monitored up to 30 days after hospital discharge.
The primary efficacy analyses were performed using the modified intent-to-treat (MITT) population, which included all treated patients who received protocol-specified surgeries and had at least 1 on-treatment primary efficacy evaluation (flatus, BM, or tolerating solid food). The Cox proportional hazard model was used to analyze treatment effect on all time-to-event data. P values for comparisons between alvimopan 6 mg and 12 mg versus placebo were calculated using the Wald 2 test. Significance conclusions were drawn based on Hochberg's step-up method for controlling the overall type I error (␣) to be 5% or less. That is, according to the Hochberg method for multiple comparisons, a P value of Յ0.025 was required to be considered statistically significant if the other treatment group's P value was Ͼ0.05. Both comparisons are considered statistically significant if both P values are Յ0.05.
The mean times to all GI events, which were also used to express the magnitude of treatment effects, were estimated using area under the Kaplan-Meier cumulative survival curve, and the difference (with 95% confidence intervals) between the alvimopan and placebo arms was provided. If an event did not occur for a patient during the study observation period (maximum 10 days postoperatively), the patient was assigned a censored time for the event. An analysis of variance model was used to analyze the treatment effect on pain, nausea, bloating, and daily postoperative opioid consumption. The differences in the frequency of treatment emergent AEs between the placebo group and each of the 2 alvimopan dose groups were assessed using Fisher exact test. An AE was defined as treatment-emergent if the event was not present at baseline and had an onset on or after the time of the first dose of study medication and up to 7 days after the last dose of study medication. An AE was also considered treatment-emergent if it was present at baseline but increased in severity after the start of study medication. All statistical analyses were performed by Adolor Corporation (Exton, PA) and were reviewed by the study authors.
RESULTS
A total of 510 patients were enrolled, randomized, and treated in the study and comprised the safety population ( Table 1 ). Of these, 41 patients were subsequently excluded from efficacy analyses: 16 in the placebo group, 14 in the alvimopan 6 mg group, and 11 in the alvimopan 12 mg group. Reasons for exclusion included lack of any postoperative efficacy evaluations because of use of epidural analgesia, NGT insertion, ileostomy or colostomy (n ϭ 21), surgical procedure not specified by the protocol (n ϭ 14), and cancellation of surgery (n ϭ 6). The remaining 469 patients comprised the MITT population. Demographic and baseline characteristics were comparable among the treatment groups ( Table 2 ). The most common operation was large bowel resection (395 patients, 84%), followed by small bowel resection (56 patients, 12%) and rTAH (18 patients, 4%). In the safety population, colon or rectal cancer was the primary indication for surgery in more than half (54%) of patients. Diverticular disease accounted for 11% of procedures, with Crohn disease (7%), ostomy reversal (7%), and intestinal polyps (6%) as other notable indications for surgery. Uterine cancer (17 patients) was the major indication for rTAH. Study drug compliance was similar among the placebo (90.1%), alvimopan 6 mg (91.6%), and alvimopan 12 mg (92.4%) groups. The mean number of days of dosing was 5.1 in the placebo group and 5.3 in both alvimopan groups. The mean number of doses was 8.4 in the placebo group, 8.8 in the alvimopan 6 mg group, and 8.6 in the alvimopan 12 mg group.
As evaluated using the Cox proportional hazards model, the time to recovery of GI function (GI-3) was significantly accelerated by alvimopan at doses of 6 mg (P Ͻ 0.05) and 12 mg (P Ͻ 0.001) when compared with placebo (Table 3) . A more pronounced treatment effect was noted in the 12 mg treatment group (Fig. 1 ). The mean time to recovery of GI function (GI-3), as estimated using the area under the Kaplan-Meier cumulative survival curve, was accelerated by approximately 15 and 22 hours in the alvimopan 6 mg and 12 mg treatment groups, respectively, compared with placebo (Table 3) .
Treatment with alvimopan 6 or 12 mg also resulted in significant improvement when compared with placebo for GI-2 (defined by the later of the following 2 events: time that the patient first tolerates solid food and the time that the patient first passes a BM) ( Table 3) . By this measure, GI recovery was accelerated by approximately 20 hours in the alvimopan 6 mg group and by 28 hours in the alvimopan 12 mg group compared with placebo. A similar trend in treatment effect was observed for the time to hospital DCO ( Table  3 ). DCOs were written approximately 13 and 20 hours earlier for the alvimopan 6 mg and 12 mg treatment groups, respectively, compared with a mean of 6 days for placebo.
The average daily postoperative opioid consumption was nearly identical for the alvimopan 12 mg group (27.1 mg) and the placebo group (27.0 mg) but was slightly higher for the alvimopan 6 mg group (33.6 mg). The slightly higher opioid consumption in the alvimopan 6 mg group, although statistically significant, was not considered clinically meaningful. Daily and maximum postoperative pain scores were comparable among the 3 treatment groups, suggesting no apparent antagonism of opioid analgesia by alvimopan.
The incidence of NGT insertion after surgery was lower for patients in the alvimopan treatment groups (8.4% and 4.8% in the 6 mg and 12 mg groups, respectively) compared with placebo (14.8%); this difference was statistically significant (P ϭ 0.004) for the 12 mg group. Treatment-emergent AEs (TEAEs) were comparable among the 3 groups (Table 4 ). The most frequent TEAEs were GI-related (nausea and vomiting), and the percentages of patients who experienced these TEAEs were slightly higher in the placebo group than in the alvimopan groups. The incidence of POI reported as a TEAE was lower in the alvimopan 6 mg (8.3%, P ϭ 0.043) and 12 mg (6.3%, P ϭ 0.005) groups compared with placebo (15.8%). The proportions of patients who discontinued treatment because of study drug-related TEAEs in the placebo, alvimopan 6 mg, and alvimopan 12 mg groups were 4.2%, 2.4%, and 3.4%, respectively. Nausea, vomiting, and POI were the most common TEAEs that led to treatment discontinuation. Treatment-emergent serious AEs considered by the investigator to be related to study drug were experienced by 2 (1.2%) patients in the placebo group, 5 (3.0%) patients in the alvimopan 6 mg group, and no patients in the alvimopan 12 mg group. No patient deaths were considered by the investigators to be related to study drug.
The numbers of patients in the safety population who were rehospitalized for any reason within 10 days after dis- *Endpoint, as defined by protocol, did not occur during the study observation period (max 10 days postoperatively) in these patients, and a censored time to event was assigned as described in Methods. † Means estimated using area under the Kaplan-Meier cumulative curve. ‡ Hazard ratio of alvimopan to placebo was calculated from the Cox proportional hazards model that included treatment. § P value was calculated from the Wald 2 tests for pairwise comparisons between alvimopan and placebo from the Cox proportional hazards model. The time to recovery of GI function (GI-3)-a composite endpoint that represents full (upper and lower) GI recovery-was defined by the later of the following 2 events: time that the patient first tolerates solid food and the time that the patient first passes either flatus or a BM. ¶ The time to recovery of GI function (GI-2)-a composite endpoint-was defined by the later of the following 2 events: time that the patient first tolerates solid food and the time that the patient first passes a BM, excluding consideration of flatus.
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Alvimopan and Postoperative Ileus charge were lower in the alvimopan treatment groups (approximately 4%) than in the placebo group (approximately 8%).
DISCUSSION
An unmet medical need exists for the effective management of POI, a common and potentially serious condition following open abdominal and pelvic surgery. No current treatments have proven to be consistently effective in the management of POI, but the development of new peripherally acting opioid receptor antagonists such as alvimopan appears promising. 4, 13 Potential benefits from prompt resolution of POI may include reduction in the incidence of bowel complications, the potential for more rapid return to normal bowel function, improved patient comfort, reduced length of hospital stay, and reduced healthcare costs. 17 Alvimopan at oral doses of 6 or 12 mg resulted in a dose-related acceleration in recovery of GI function in our MITT study population, consisting primarily (96%) of patients undergoing laparotomy for bowel resection. The time to recovery of GI function as defined by the primary (GI-3) and secondary (GI-2) efficacy endpoints are critical events during the postoperative course and the clinical indicators for resolution of POI. Statistically significant and clinically meaningful improvement in both of these measures of GI recovery occurred in both alvimopan treatment groups.
This acceleration in the recovery of GI function could be expected to have a beneficial impact on patient recovery and reduced postoperative morbidity, including POI, small bowel obstruction, insertion of NGT, hospital length of stay, and readmission. In our study, the accelerated recovery of GI function in the alvimopan treatment groups corresponded to an earlier time to hospital DCO. Compared with placebo, time to discharge in the alvimopan 12 mg group was reached approximately 1 day earlier, which has potentially beneficial implications for overall healthcare costs. This accelerated time to hospital discharge is particularly notable in the context of the time to hospital discharge for the placebo population in this study (146 hours ϭ 6.1 days), which is shorter than a recently published meta-analysis of 8 open colectomy studies (mean length of stay ϭ 6.9 and 10.3 days for patients Ͻ70 and Ͼ70 years old, respectively). 18 Placebo mean length of stay was likely shorter than published averages due to the protocol-specified fast-track procedures used in the study (eg, early ambulation, progression of diet, and removal of NGT). A significant reduction in the incidence of postoperative NGT insertion was observed in patients treated with alvimopan 12 mg. Use of NGT may cause significant patient discomfort, and routine use following abdominal surgery is no longer recommended. 11 Furthermore, studies have shown that NGT decompression does not shorten the duration of ileus and may, in some cases, contribute to postoperative complications such as nasal and pharyngeal injury, fever, atelectasis, increased gastric reflux, regurgitation, and pneumonia. 5,19 -22 Another aspect of postoperative care that contributes to the prolongation of POI is the widespread use of opioids, which are still considered the gold standard for management of pain following major surgery. Opioids are known to delay gastric emptying and disrupt normal motility in the small bowel and colon, thus prolonging recovery from POI. [23] [24] [25] There is some suggestion that endogenous opioids and/or endogenous opioid peptides may also play a role in various postoperative responses, including ileus, which deserve further investigation. 26 The potent effect of opioids on GI motility are primarily mediated through opioid receptors within the enteric nervous system. 24 Alvimopan competitively binds to opioid receptors and has low and variable oral bioavailability. 12 Alvimopan is proposed to act within the GI tract, thereby reducing the GI side effects of opioids without affecting their centrally mediated analgesia. 12 Indeed, a series of clinical pharmacology studies indicated that alvimopan selectively reversed the negative GI effects of morphine 12 and, in the present study, treatment with alvimopan did not appear to antagonize opioid analgesia, based on comparable VAS pain scores among the 3 treatment groups. Additionally, opioid consumption was comparable in the alvimopan 12 mg and placebo treatment groups, suggesting that alvimopan was active in the periphery and not in the central nervous system.
In conclusion, alvimopan at doses of 6 or 12 mg b.i.d. in our study accelerated recovery of GI function in patients undergoing laparotomy for bowel resection or radical hysterectomy, with no evidence of antagonism of opioid analgesia as measured by VAS pain scores. Additionally, the 12-mg dose significantly shortened the time to hospital DCO by approximately 1 day. Outcomes associated with this acceler- ated GI recovery included similar trends in all secondary time to event endpoints, a lower incidence of NGT reinsertion, nausea, vomiting, and hospital readmission. These clinically beneficial outcomes were achieved without increased risk, as measured by comparable incidences of AEs between active treatment and placebo groups, and without increased postoperative morbidity associated with these types of major abdominal and pelvic operations. Undoubtedly every surgeon who performs bowel resections would agree that postoperative ileus remains an unsolved problem and one of the main causes of prolonged hospitalization and readmission after abdominal surgery. The manuscript suggests that an effective treatment could potentially save 1.1 billion dollars-that is with a "B"-per year in hospital costs. With those kinds of numbers at stake, one can understand why pharmaceutical companies are interested in postoperative ileus.
We have known for a long time that opioids delay gastric emptying and disrupt normal motility in the small bowel and colon, and that these effects are mediated primarily through the mu opioid receptors within the enteric nervous system.
The unique properties of this particular drug, alvimopan, that make it such an exciting therapy for postoperative ileus are that it competitively binds to the mu opioid receptors at the enteric gut level but does not interfere with the CNS-mediated analgesia. This study I think clearly showed that oral alvimopan is effective.
I have 3 questions for Dr. Wolff. The first has to do with statistics. I noted that the Adolor Corporation performed the statistical analyses in this study. Was there any independent review of their analyses by a Mayo Clinic or other biostatistician independent of the company?
Could you comment on the fact that of the 56 small bowel resections in your study, 21% were in the placebo group while 37% and 41% were in the 6 milligram and 12 milligram alvimopan groups respectively? Could these differences have influenced your results? Second, have you or are you planning to do other studies to address other issues that come to mind, including appropriate dosing? It appears that 12 milligrams is better than 6 milligrams. Is 18 milligrams better than 12? What about studies in other populations such as those in whom epidural analgesia is used? What about patients who are already on narcotics or patients who have Ogilvie's syndrome? What about laparoscopic resections?
Finally, have you done a cost analysis study to suggest how much of the $1.1 billion might be impacted by a 22-hour decrease in postop ileus? DR. JOSEPH M. VAN DE WATER (MACON, GEORGIA): I would like to continue on one of the points that Dr. Rothenberger brought up. And that is, since it has been shown that bowel movements will occur when used in chronic opioid users if the dose is as low a .5 to 1 milligram per day, what, in your speculation, is going on in these postoperative patients which necessitates a higher dose? Does trauma or the operation itself, stress, cause a greater expression of the mu opioid receptors in the bowel wall? Why do we need more Alvimopan?
DR. MERRIL T. DAYTON (BUFFALO, NEW YORK): As Dr. Rothenberger mentioned, trying to find the cause of postoperative ileus has become a Holy Grail of sorts for GI surgeons. While we don't have the complete answer, I think in the last 10 years we have learned that narcotics play a central role-in fact, some people think it is the predominant role-in causing postoperative ileus.
Just before I left to come to this meeting one of my faculty members showed me a protocol for post-op pain management that included some preliminary data demonstrating success in using a combination of Cox 2 inhibitors preand postoperatively, Ketoralac, and epidural anesthesia for all postoperative pain; narcotics were never used.
Is it possible that rather than giving an opioid receptor antagonist we ought to avoid narcotics altogether with some of these novel new analgesics that are available? DR. FRANK G. MOODY (HOUSTON, TEXAS): Did you do a sub-cohort analysis of individuals that probably were at high risk for pathologic ileus-in other words, a prolonged ileus? Did you have in your bowel group, patients that had inflammatory disease of the small or large intestine? This would make a big difference. In addition, do you know of any information on opioid antagonists specifically in terms of the ileus associated with acute pancreatitis? DR. BRUCE G. WOLFF (ROCHESTER, MINNESOTA): Thank you for those questions and comments. Dr. Rothenberger, I will start with your questions first.
The short answer is, yes, there was an outside review of this data. In fact, this represents 1 of 4 randomized control trials of 2000 patients, of whom 1500 patients have received the drug. Perhaps the toughest arbiter in all of this is the FDA, and the company will be seeking FDA approval. And as you know, that is a very rigorous procedure, particularly for a drug as compared to a device.
And while we are discussing this, I think it is a good time to talk about companies who sponsor studies like this and our role in them. Because this is a new era. I think we are seeing more and more of this type of study, and we have to be very careful. I think our influence has to be present in terms of the conception and design of the study, of the statistical analysis, the interpretation of the results, and particularly in preparation of the manuscripts to ensure that the conclusions are justified in this type of study. And I can say that many of us, Dr. Michelassi, myself, and many others, have had this type of input into this particular study.
What we are not going to have, realistically, is data management. No company is going to simply give you a drug or device and give you a pile of money and say, "Please tell us if this works." It just doesn't work that way. So there is a certain compromise here. There has to be an element of trust. Otherwise, we are not going to see exciting new things like this come along without the element of capital enterprise behind them. But we have a very important responsibility in such studies as this.
Dr. Rothenberger, as to the small bowel resection group, there were small numbers, 56, as you mentioned. This is just the way the randomized scheme developed in this particular group, or just the way the cookie crumbled.
Higher doses. The dose response plateaus at 12 milligrams. Higher doses don't give you added benefit. The drug does have to be started before opiates are given, or, if you will, before the induction of anesthesia. The drug works through a competitive inhibition type of process and it must occupy the receptors before the opiates arrive.
In epidural patients we don't see any added benefit. As you know, that is a different way of providing analgesia, and opiates aren't generally given. So it would be inconsistent to use this type of management regimen with an epidural.
In chronic users, opiate users, or addicts, the drug right now is contraindicated because these patients are very sensitive to this drug and even small amounts sometimes can precipitate cramping, abdominal pain, nausea, vomiting, and diarrhea in a crisis type of a fashion. And of course, if you give opiates, it relieves it. Nevertheless, it has been used, and is being investigated for a role in the management of opiateinduced constipation and improving that condition in such patients.
Laparoscopic surgery. Several of my colleagues are thinking about this and investigating this further. They think that this might be of use if there is a gain of perhaps 12 hours with the use of this drug, in patients undergoing laparoscopic procedures, who do have an element of ileus. But those studies have not been conceived of as yet.
There is a cost effect. The data is very soft on cost of a hospital day, mean or median cost versus charge. And you know there is a huge gap there. And then there is always the discount that comes in depending on who is paying for the day. As you know, hospital day one and day two are very expensive and then expense drops off; there is a bell-shaped curve, and it starts to rise again on postoperative day five. The cost of a day in the hospital to manage ileus can be as high as $1,500. That sort of data is being generated and should be available within the next 6 to 12 months.
Dr. Van De Water, I have to say flatly that I don't know the answer to your question. That has not come up as yet. It is an interesting speculation, but that is what it would be if I tried to answer that.
Dr. Dayton, we haven't investigated other of the newer analgesic agents and opiates, so I can't answer your question as yet as far as the use of other agents to provide analgesia. Of course, it would be a good thing if we could find comparable drugs to narcotics that produce the same effect, but I am not sure that we are anywhere close to that at this point.
Dr. Moody, prolonged ileus patients at high risk-we didn't see in this study any difference in the IBD patients versus other patients as far as development of prolonged ileus. There undoubtedly will be subset analysis, or subset studies in various types of patients to see if there are certain groups of patients who will benefit from this regimen more than others, rather than giving it to every patient that undergoes an abdominal procedure. It has been used in gynecologic procedures and so forth. So there is quite a bit of work yet to be done.
